BioCentury
ARTICLE | Clinical News

Advisory panel narrowly rejects olicerideine for acute pain

October 12, 2018 7:30 PM UTC

FDA’s Anesthetic and Analgesic Drug Products Advisory Committee voted 8-7 against recommending approval of oliceridine (TRV130) from Trevena Inc. (NASDAQ:TRVN) to manage moderate to severe pain in adults for whom IV opioids are warranted.

Panelists who voted for approval thought oliceridine was at least as safe as morphine and might eventually prove to be safer, and could address unmet needs for patients allergic to or intolerant of morphine. They also thought it could be advantageous due to its fast onset and washout...

BCIQ Company Profiles

Trevena Inc.